Table I.
Comparison of the clinical and molecular characteristics of patients with AML stratified according to the expression of miR-500.
| Characteristics | miR-500low (n=37) | miR-500high (n=37) | Statistics | P-value |
|---|---|---|---|---|
| Median age (range), years | 49 (22–72) | 53 (18–65) | U=654.0 | 0.741 |
| Age group, n (%) | χ2=1.096 | 0.295 | ||
| <60 years | 29 (78.4) | 25 (67.6) | ||
| ≥60 years | 8 (21.6) | 12 (32.4) | ||
| Sex, n (%) | χ2=0.881 | 0.348 | ||
| Male | 19 (51.4) | 23 (62.2) | ||
| Female | 18 (48.6) | 14 (37.8) | ||
| Median white blood cell count (range), ×109/l | 30.9 (0.6–202.7) | 27.1 (0.8–233.8) | U=742.5 | 0.531 |
| |Median bone marrow blasts (range), % | 67 (34–100) | 75 (30–97) | U=592.0 | 0.317 |
| Median peripheral blood blasts (range), % | 48 (0–96) | 45 (0–90) | U=791.6 | 0.166 |
| French-American-British subtype, n (%) | χ2=17.709 | 0.024 | ||
| M0 | 5 (13.5) | 4 (10.8) | 0.722 | |
| M1 | 9 (24.3) | 14 (37.8) | 0.209 | |
| M2 | 15 (40.5) | 4 (10.8) | 0.003 | |
| M3 | 2 (5.4) | 0 (0.0) | 0.152 | |
| M4 | 5 (13.5) | 9 (24.3) | 0.235 | |
| M5 | 0 (0.0) | 4 (10.8) | 0.040 | |
| M6 | 0 (0.0) | 1 (2.7) | 0.314 | |
| M7 | 0 (0.0) | 1 (2.7) | 0.314 | |
| Karyotype, n (%) | χ2=16.216 | 0.063 | ||
| Normal | 13 (35.1) | 21 (56.8) | 0.062 | |
| Complex | 5 (13.5) | 7 (18.9) | 0.528 | |
| 8 Trisomy | 3 (8.1) | 3 (8.1) | 1.000 | |
| inv(16)/core-binding factor subunit | 5 (13.5) | 0 (0.0) | 0.021 | |
| β-myosin heavy chain 11 | ||||
| 11q23/lysine methyltransferase 2A | 0 (0.0) | 3 (8.1) | 0.077 | |
| −7/7q- | 2 (5.4) | 1 (2.7) | 0.556 | |
| t(15;17)/promyelocytic leukemia-retinoic acid receptor α | 2 (5.4) | 0 (0.0) | 0.152 | |
| t(9;22)/BCR activator of RhoGEF and GTPase-ABL proto-oncogene 1, non-receptor tyrosine kinase | 1 (2.7) | 1 (2.7) | 1.000 | |
| t(8;21)/runt-related transcription factor | 1 (2.7) | 0 (0.0) | 0.314 | |
| 1- RUNX1 translocation partner 1 | ||||
| Other/undefined subtypes | 5 (13.5) | 1 (2.7) | 0.088 | |
| Molecular risk stratification, n (%) | χ2=9.776 | 0.021 | ||
| Good | 8 (21.6) | 0 (0.0) | 0.003 | |
| Intermediate | 18 (48.6) | 23 (62.2) | 0.242 | |
| Poor | 11 (29.7) | 13 (35.1) | 0.619 | |
| Fms-related tyrosine kinase 3, n (%) | χ2=1.909 | 0.167 | ||
| Mutation | 6 (16.2) | 11 (29.7) | ||
| Wild-type | 31 (83.8) | 26 (70.3) | ||
| Nucleophosmin 1, n (%) | χ2=6.852 | 0.009 | ||
| Mutation | 5 (13.5) | 15 (40.5) | ||
| Wild-type | 32 (86.5) | 22 (59.5) | ||
| CCAAT enhancer binding protein α, n (%) | χ2=5.345 | 0.069 | ||
| Single mutation | 4 (10.8) | 1 (2.7) | ||
| Double mutation | 3 (8.1) | 0 (0.0) | ||
| Wild-type | 30 (81.1) | 36 (97.3) | ||
| DNA methyltransferase 3α, n (%) | χ2=0.294 | 0.588 | ||
| Mutation | 10 (27.0) | 8 (21.6) | ||
| Wild-type | 27 (73.0) | 29 (78.4) | ||
| Isocitrate dehydrogenase (NADP(+)) | χ =0.107 | 0.744 | ||
| 1, cytosolic, n (%) | ||||
| Mutation | 5 (13.5) | 6 (16.2) | ||
| Wild-type | 32 (86.5) | 31 (83.8) | ||
| Isocitrate dehydrogenase, n (%) [NADP(+)] | χ2=0.561 | 0.454 | ||
| 2, mitochondrial | ||||
| Mutation | 3 (8.1) | 5 (13.5) | ||
| Wild-type | 34 (91.9) | 32 (86.5) | ||
| WT1 transcription factor, n (%) | χ2=0.126 | 0.722 | ||
| Mutation | 5 (13.5) | 4 (10.8) | ||
| Wild-type | 32 (86.5) | 33 (89.2) | ||
| Runt-related transcription factor 1, n (%) | χ2=2.242 | 0.134 | ||
| Mutation | 2 (5.4) | 6 (16.2) | ||
| Wild-type | 35 (94.6) | 31 (83.8) | ||
| Lysine methyltransferase 2A, n (%) | χ2=1.507 | 0.304 | ||
| Mutation | 1 (2.7) | 3 (8.1) | ||
| Wild-type | 36 (97.3) | 34 (91.9) | ||
| NRAS/KRAS proto-oncogene GTPase, n (%) | χ2=3.945 | 0.047 | ||
| Mutation | 6 (16.2) | 1 (2.7) | ||
| Wild-type | 31 (83.8) | 36 (97.3) | ||
| Tet methylcytosine dioxygenase 2, n (%) | χ2=1.057 | 0.304 | ||
| Mutation | 3 (8.1) | 1 (2.7) | ||
| Wild-type | 34 (91.9) | 36 (97.3) | ||
| Tumor protein 53, n (%) | χ2=1.057 | 0.304 | ||
| Mutation | 1 (2.7) | 3 (8.1) | ||
| Wild-type | 36 (97.3) | 34 (91.9) | ||
| KIT proto-oncogene, receptor tyrosine kinase, n (%) | χ2=1.057 | 0.304 | ||
| Mutation | 3 (8.1) | 1 (2.7) | ||
| Wild-type | 34 (91.9) | 36 (97.3) | ||
| Protein tyrosine phosphatase non-receptor type 11, n (%) | χ2=1.930 | 0.165 | ||
| Mutation | 1 (2.7) | 4 (10.8) | ||
| Wild-type | 36 (97.3) | 33 (89.2) | ||
| PHD finger protein 6, n (%) | ||||
| Mutation | 0 (0.0) | 4 (10.8) | χ2=4.229 | 0.040 |
| Wild-type | 37 (100.0) | 33 (89.2) | ||
| Relapse, n (%) | χ2=0.063 | 0.802 | ||
| Yes | 26 (70.3) | 25 (67.6) | ||
| No | 11 (29.7) | 12 (32.4) | ||
| Source of hematopoietic stem, n (%) cell transplantation | χ2=4.900 | 0.086 | ||
| Haplogeneic | 2 (5.4) | 0 (0.0) | ||
| Sib allogeneic | 12 (32.4) | 20 (54.1) | ||
| Matched unrelated donor | 23 (62.2) | 17 (45.9) | ||
U, Mann-Whitney U; t, translocation; sib, matched sibling.